• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CXCR4拮抗剂R54靶向人卵巢癌细胞中的上皮-间质转化（EMT）。

The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.

作者信息

Russo Daniela, Spina Anna, Portella Luigi, Bello Anna Maria, Galdiero Francesca, Trotta Anna Maria, Ieranò Caterina, Rea Giuseppina, Cecere Sabrina Chiara, Coppola Elisabetta, Di Maro Salvatore, Pignata Sandro, Califano Daniela, Scala Stefania

机构信息

Microenvironment Molecular Targets, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Naples, Italy.

Uro-Gynecologic Oncology Unit, Istituto Nazionale Tumori IRCCS-Fondazione "G. Pascale", Naples, Italy.

出版信息

PLoS One. 2024 Dec 19;19(12):e0314735. doi: 10.1371/journal.pone.0314735. eCollection 2024.

DOI:10.1371/journal.pone.0314735
PMID:39700131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11658595/
Abstract

The axis CXCL12-CXCR4 is highly expressed in ovarian cancer where contributes to disease progression. Aim of the work was to evaluate the effect of the newly developed CXCR4 antagonist R54 on human ovarian cancer cells aggressiveness. CXCL12-CXCR4 axis was evaluated in human ovarian cancer cells through proliferation, migration and signaling CXCL12-dependents. Epithelial to mesenchymal transition (EMT) was analyzed through E-CADHERIN, N-CADHERIN, VIMENTIN, SNAIL1 and ΒETA-CATENIN by qRT-PCR, immunofluorescence and immunoblotting. R54 inhibited ovarian cancer cells proliferation and migration CXCL12-induced. Moreover, R54 inhibited CXCL12 dependent pERK1/2 and pAKT and reversed the CXCL12 induced EMT in ovarian cancer cells. Targeting CXCR4 with the new antagonist R54 consistently reverted the mesenchymal transition in human ovarian cancer cells reducing migratory and chemoresistance features.

摘要

轴CXCL12 - CXCR4在卵巢癌中高表达，其有助于疾病进展。本研究的目的是评估新开发的CXCR4拮抗剂R54对人卵巢癌细胞侵袭性的影响。通过增殖、迁移和CXCL12依赖性信号传导来评估人卵巢癌细胞中的CXCL12 - CXCR4轴。通过qRT - PCR、免疫荧光和免疫印迹，利用E - 钙黏蛋白、N - 钙黏蛋白、波形蛋白、SNAIL1和β - 连环蛋白分析上皮 - 间充质转化（EMT）。R54抑制CXCL12诱导的卵巢癌细胞增殖和迁移。此外，R54抑制CXCL12依赖性的pERK1/2和pAKT，并逆转CXCL12诱导的卵巢癌细胞EMT。用新型拮抗剂R54靶向CXCR4可一致地逆转人卵巢癌细胞的间充质转化，降低其迁移和化疗耐药特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/8fbf0b41f8f7/pone.0314735.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/75b6f9ac9249/pone.0314735.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/208621f58f93/pone.0314735.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/033420429a86/pone.0314735.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/b4a769c9fc0a/pone.0314735.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/8fbf0b41f8f7/pone.0314735.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/75b6f9ac9249/pone.0314735.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/208621f58f93/pone.0314735.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/033420429a86/pone.0314735.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/b4a769c9fc0a/pone.0314735.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe6f/11658595/8fbf0b41f8f7/pone.0314735.g005.jpg

相似文献

1
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.CXCR4拮抗剂R54靶向人卵巢癌细胞中的上皮-间质转化（EMT）。
PLoS One. 2024 Dec 19;19(12):e0314735. doi: 10.1371/journal.pone.0314735. eCollection 2024.
2
CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.CXCR7 并非人卵巢癌细胞上皮间质转化所必需的 CXCL12-CXCR4 诱导因素。
Mol Carcinog. 2019 Jan;58(1):144-155. doi: 10.1002/mc.22916. Epub 2018 Oct 16.
3
Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.CXCL12-CXCR4 轴在卵巢癌转移中的作用及 AMD3100 阻断 CXCL12-CXCR4 抑制肿瘤细胞体外迁移和侵袭。
J Cell Physiol. 2019 Apr;234(4):3897-3909. doi: 10.1002/jcp.27163. Epub 2018 Sep 7.
4
Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis.肿瘤相关成纤维细胞通过 CXCL12/CXCR4 轴诱导卵巢癌细胞上皮间质转化和顺铂耐药。
Future Oncol. 2020 Nov;16(32):2619-2633. doi: 10.2217/fon-2020-0095. Epub 2020 Aug 17.
5
Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.堕胎药米非司酮（RU486衍生物）通过中断CXCL12/CXCR4轴来预防卵巢转移。
Mol Carcinog. 2017 Aug;56(8):1896-1908. doi: 10.1002/mc.22645. Epub 2017 Mar 30.
6
The CXCL12-CXCR4 axis promotes migration, invasiveness, and EMT in human papillary thyroid carcinoma B-CPAP cells via NF-κB signaling.CXCL12-CXCR4轴通过NF-κB信号通路促进人甲状腺乳头状癌B-CPAP细胞的迁移、侵袭和上皮-间质转化。
Biochem Cell Biol. 2018 Oct;96(5):619-626. doi: 10.1139/bcb-2017-0074. Epub 2018 Jan 9.
7
[Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].趋化因子轴CXCL12-CXCR4与上皮性卵巢癌的关系
Zhonghua Yi Xue Za Zhi. 2013 Jun 4;93(21):1677-80.
8
AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.AMD3100 通过阻断前列腺癌中的 SDF-1α/CXCR4 信号通路抑制肝和肺中的上皮-间充质转化、细胞侵袭和转移。
J Cell Physiol. 2019 Jul;234(7):11746-11759. doi: 10.1002/jcp.27831. Epub 2018 Dec 7.
9
Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.吉非替尼通过 TGF-β1 信号通路促进 EGFR 突变肺癌细胞中 CXCR4 依赖性上皮间质转化。
Clin Transl Oncol. 2020 Aug;22(8):1355-1363. doi: 10.1007/s12094-019-02266-w. Epub 2020 Jan 3.
10
Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.抑制 CXCR4 通过 Hippo-YAP 信号通路调节 NSCLC 的上皮间质转化。
Cell Biol Int. 2018 Sep;42(10):1386-1394. doi: 10.1002/cbin.11024. Epub 2018 Jul 17.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.CXCL12-CXCR4/CXCR7 轴在癌症中的作用：从机制到临床应用。
Int J Biol Sci. 2023 Jun 26;19(11):3341-3359. doi: 10.7150/ijbs.82317. eCollection 2023.
3
Tissue Expression and Prognostic Role of CXCL12 and CXCR4 in High-grade Serous Ovarian Carcinoma.
CXCL12 和 CXCR4 在高级别浆液性卵巢癌中的组织表达和预后作用。
Anticancer Res. 2023 Jul;43(7):3331-3340. doi: 10.21873/anticanres.16509.
4
Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α.肿瘤相关成纤维细胞通过旁分泌 SDF-1α 促进人卵巢癌转移和凋亡抵抗。
Clin Transl Oncol. 2023 Jun;25(6):1606-1616. doi: 10.1007/s12094-022-03054-9. Epub 2023 Jan 2.
5
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.肿瘤进展和转移中 EMT 的分子机制和治疗策略。
J Hematol Oncol. 2022 Sep 8;15(1):129. doi: 10.1186/s13045-022-01347-8.
6
Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy.CXCL12/CXCR4拮抗剂与基于纳米的癌症治疗药物递送系统的最新进展
Pharmaceutics. 2022 Jul 25;14(8):1541. doi: 10.3390/pharmaceutics14081541.
7
Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells.免疫检查点 PD-1 和趋化因子受体 4（CXCR4）的相互作用促进了胰腺癌细胞的恶性表型。
PLoS One. 2022 Jul 7;17(7):e0270832. doi: 10.1371/journal.pone.0270832. eCollection 2022.
8
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.肿瘤/基质CXCR4-CXCL12-CXCR7在MITO16A/MaNGO-OV2晚期卵巢癌患者中的生物学作用
Cancers (Basel). 2022 Apr 6;14(7):1849. doi: 10.3390/cancers14071849.
9
Advances in ovarian cancer, from biology to treatment.卵巢癌的进展：从生物学到治疗
Nat Cancer. 2021 Jan;2(1):6-8. doi: 10.1038/s43018-020-00166-5.
10
Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.通过上皮-间充质转化特征和同源重组修复基因对高级别浆液性卵巢癌进行分类。
Genes (Basel). 2021 Jul 20;12(7):1103. doi: 10.3390/genes12071103.